The efficacy of adding targeted agents to neoadjuvant therapy for locally advanced rectal cancer patients: a meta‐analysis. (21st February 2018)

• Record Type: Journal Article
• Authors: Zhong, Xi; Wu, Zhonghua; Gao, Peng; Shi, Jinxin; Sun, Jingxu; Guo, Zhexu; Wang, Zhenning; Song, Yongxi
• Is Part Of: Cancer medicine. Volume 7:Number 3(2018:Mar.)
• Page Start: 565
• Page End: 582
• Publication Date: 2018-02-21
• Subjects: Efficacy -- neoadjuvant therapy -- pathologic complete response -- rectal cancer -- targeted agents; 616.994005
• DOI: 10.1002/cam4.1298
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Patients with locally advanced rectal cancer (LARC) are at tremendous risk of metastatic diseases. To improve the prognoses of LARC patients, the efficacy of adding targeted agents to neoadjuvant therapy has been investigated by many researchers but remains controversial. A literature search of relevant databases was conducted through December 2016, 804 studies were identified and 32 investigations were ultimately included. A total of 1196 patients from 31 cohorts of 29 studies were eligible for quantitative synthesis in this single‐arm setting meta‐analysis. As pathologic complete response (pCR) shows promise as a prognosis indicator, we focused on pCR rates to evaluate whether adding targeted agents to neoadjuvant therapies improves the outcome of LARC patients. In our study, we revealed pooled estimates of pCR of 27% (95%CI, 21–34%) and 14% (95%CI, 9–21%) for bevacizumab‐relevant cohorts and cetuximab‐relevant cohorts, respectively. The safety of adding targeted agents to neoadjuvant therapy was also evaluated by pooling the data of Grade 3/4 toxicity. In conclusion, our study revealed that adding bevacizumab to the neoadjuvant therapy regimens provides appreciable pCR for LARC patients. Meanwhile, the efficacy of cetuximab remains inconclusive, RCTs with larger scale and better study design that stress more on mutational status are needed. Abstract : Since pathologic complete response (pCR) shows promise as a prognosis indicator, in this meta‐analysis we pooled the data of pCR rates extracted from the included studies to evaluate whether adding targeted agents to neoadjuvant therapies improves the outcome of LARC patients. Our study revealed that adding bevacizumab to the neoadjuvant therapy regimens provides an appreciable pCR for LARC patients. Meanwhile, cetuximab fails to benefit LARC patients when the administration is not conducted based on their KRAS status.